Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia
Trial Parameters
Brief Summary
The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.
Eligibility Criteria
Inclusion Criteria: * Infants with initial diagnosis of biliary atresia with biliary atresia score \> 23.927 will be allocated for Kasai porto-enterostomy with intra-operative cholangiogram reaching type 3 biliary atresia anatomy as a final diagnosis. Exclusion Criteria: * Major cardiac, renal, pulmonary, neurological malformations or illnesses. * Hemoglobinopathies, such as sickle cell anemia * Active systemic infection. * White blood cell count \> 20,000 cells/mm3. * Platelet count \< 40,000 cells/mm3 or ≥ 800,000 cells/mm3. * Purpura fulminans or unexplained vascular thrombotic conditions.